Literature DB >> 1688809

Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease.

T Aoyagi1, T Wada, M Nagai, F Kojima, S Harada, T Takeuchi, H Takahashi, K Hirokawa, T Tsumita.   

Abstract

We examined the changes in the intracerebral activities, at the time of postmortem autopsy, in patients with Alzheimer's disease. When compared with the control group, the activity of kallikrein-like enzyme was significantly decreased, while prolyl endopeptidase activity increased, in the patients group. Aprotinin inhibited 50% of the activity of the former enzyme at 2 x 10(-7) M. Taken together with the results of a multivariate study, the above findings may indicate that intracerebral kallikrein deficiency plays an important role in the pathogenesis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688809     DOI: 10.1007/bf01955428

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  21 in total

1.  Studies on human salivary kallikrein. II. Properties of purified salivary kallikrein.

Authors:  Y Fujimoto; C Moriwaki; H Moriya
Journal:  J Biochem       Date:  1973-08       Impact factor: 3.387

2.  Three modes of age-related changes of hydrolytic enzymes in murine brain.

Authors:  T Aoyagi; T Wada; F Kojima; M Nagai; M Osanai; K Imahori; H Umezawa
Journal:  Biotechnol Appl Biochem       Date:  1986-02       Impact factor: 2.431

Review 3.  Cathepsin B, Cathepsin H, and cathepsin L.

Authors:  A J Barrett; H Kirschke
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

4.  Studies on urinary kallikreins. I. Purification and characterization of human urinary kallikreins.

Authors:  Y Matsuda; K Miyazaki; H Moriya; Y Fujimoto; Y Hojima; C Moriwaki
Journal:  J Biochem       Date:  1976-10       Impact factor: 3.387

5.  Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains.

Authors:  G Perry; R Friedman; G Shaw; V Chau
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Human plasma kallikrein. A rapid purification method with high yield.

Authors:  H Nagase; A J Barrett
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

7.  A zinc metalloendopeptidase associated with dog pancreatic membranes.

Authors:  R A Mumford; A W Strauss; J C Powers; P A Pierzchala; N Nishino; M Zimmerman
Journal:  J Biol Chem       Date:  1980-03-25       Impact factor: 5.157

8.  Highly sensitive peptide-4-methylcoumaryl-7-amide substrates for blood-clotting proteases and trypsin.

Authors:  S Kawabata; T Miura; T Morita; H Kato; K Fujikawa; S Iwanaga; K Takada; T Kimura; S Sakakibara
Journal:  Eur J Biochem       Date:  1988-02-15

9.  Vasopressin metabolite, AVP4-9, binding sites in brain: distribution distinct from that of parent peptide.

Authors:  R E Brinton; D R Gehlert; J K Wamsley; Y P Wan; H I Yamamura
Journal:  Life Sci       Date:  1986-02-03       Impact factor: 5.037

10.  Abnormality of the post-proline-cleaving enzyme activity in mice with systemic lupus erythematosus-like syndrome.

Authors:  T Aoyagi; T Wada; F Kojima; M Nagai; M Okubo; Y Masaki; H Umezawa
Journal:  J Appl Biochem       Date:  1985 Aug-Oct
View more
  6 in total

1.  Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain.

Authors:  K Toide; T Fujiwara; Y Iwamoto; M Shinoda; K Okamiya; T Kato
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

Review 2.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

3.  Deficiency of fibrinolytic enzyme activities in the serum of patients with Alzheimer-type dementia.

Authors:  T Aoyagi; T Wada; F Kojima; M Nagai; S Harada; T Takeuchi; K Isse; M Ogura; M Hamamoto; K Tanaka
Journal:  Experientia       Date:  1992-07-15

Review 4.  Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity.

Authors:  Timo T Myöhänen; J Arturo García-Horsman; Jofre Tenorio-Laranga; Pekka T Männistö
Journal:  J Histochem Cytochem       Date:  2009-05-26       Impact factor: 2.479

5.  Therapeutic Effect of Novel Cyanopyrrolidine-Based Prolyl Oligopeptidase Inhibitors in Rat Models of Amnesia.

Authors:  Nikolay N Zolotov; Igor A Schepetkin; Tatyana A Voronina; Vladimir F Pozdnev; Andrei I Khlebnikov; Irina V Krylova; Mark T Quinn
Journal:  Front Chem       Date:  2021-12-22       Impact factor: 5.221

6.  Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.

Authors:  Hengjing Cui; Tommi Kilpeläinen; Lydia Zouzoula; Samuli Auno; Kalevi Trontti; Sampo Kurvonen; Susanna Norrbacka; Iiris Hovatta; Poul Henning Jensen; Timo T Myöhänen
Journal:  J Cell Mol Med       Date:  2021-09-05       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.